Pharmaceutical Company CollaborationsDisease Foundation CollaborationsFederal
CombinatoRx collaborates with pharmaceutical and biotechnology companies to support the full development and commercialization of selected product candidates to obtain access to additional development, financial or commercial resources including sales forces. Pharmaceutical Corporations CollaborationsNovartisIn May 2009, CombinatoRx and Novartis entered into a strategic alliance focused on the discovery of novel anti-cancer combinations. The collaboration explores combination effects in cell lines representing a broad spectrum of cancers to provide a robust and systematic understanding of combination therapy opportunities. The alliance also explores important differences in response by cancer type, including genotype and other mutational differences. Each party will contribute compounds from its compound library and evaluate the anti-cancer effects by utilizing CombinatoRx’s proprietary combination high throughput screening (cHTS™) platform and Chalice analyzer software. Under the agreement, CombinatoRx received a $4 million upfront payment and funding for research support for two years. In addition, for each combination advanced to the market from the collaboration, CombinatoRx is eligible to receive up to $58 million in clinical, regulatory and commercial milestones. The alliance has an initial two-year term that may be extended by Novartis for three additional one-year periods. CombinatoRx retains the right to conduct oncology research on its own behalf as well as partner with others in the field of oncology, and will retain certain intellectual property rights which may arise from the collaboration research. Fovea Pharmaceuticals SAIn January 2006, CombinatoRx entered into a research and license agreement with Fovea Pharmaceuticals in which Fovea agreed to fund and develop selected CombinatoRx product candidates for ophthalmic diseases up to the start of Phase III trials (Full News Release). In exchange for Fovea's development investment, CombinatoRx will grant Fovea exclusive commercial rights to these products in Europe and certain additional countries. CombinatoRx will retain commercialization rights to North America. The companies will have co-exclusive rights in Japan and Taiwan. Separately, CombinatoRx licensed to Fovea an exclusive worldwide right to certain preclinical drug combinations to treat specified indications. CombinatoRx is eligible to receive up to $20 million in upfront and milestone payments for the first product, an additional milestone payment for the approval of a product in an additional indication, and royalties on cumulative net sales. Angiotech Pharmaceuticals, Inc.In June 2007, Angiotech Pharmaceuticals, Inc. extended their collaboration with CombinatoRx based upon the successful advancement of a number of product candidates in relevant preclinical models. The joint research being conducted under the agreement to create next generation drug device and local medicines has been extended beyond the initial two and a half year term to a total of five years, resulting in a $7 million payment to CombinatoRx due before October 3, 2007 (Full News Release). In October 2005, CombinatoRx and Angiotech entered into a research and license agreement which granted Angiotech an option to evaluate and exclusively license compounds selected by Angiotech from the CombinatoRx clinical and preclinical pipeline and its proprietary bioinformatics database of synergistic combination pharmaceuticals for development and potential commercialization in certain medical device and local interventional applications (Full News Release). CombinatoRx also agreed to deploy its proprietary combination High Throughput Screening (cHTS™) technology in a joint multi-year research initiative to identify novel drug combinations for multiple areas of strategic importance to Angiotech. Intellectual property from this research project will be jointly owned, and exclusively cross licensed to CombinatoRx for traditional pharmaceutical uses outside the Angiotech fields of use. Under the terms of the agreement, Angiotech has made an upfront license execution payment of $27 million to CombinatoRx plus a $15 million equity investment in CombinatoRx entitling Angiotech to license up to ten CombinatoRx compounds for the Angiotech field, and up to five more compounds for an additional payment of $2 million per compound. Intellectual property from the research project component of the agreement is exclusively licensed to Angiotech in the Angiotech fields of use. CombinatoRx is eligible to receive development and regulatory milestone payments of up to $30 million for each product selected by Angiotech for development, in addition to royalties on cumulative commercial sales of such products. Disease Foundation CollaborationsCharley’s Fund and the Nash Avery FoundationIn November 2007, we entered into a sponsored research collaboration agreement with an entity formed by Charley’s Fund and the Nash Avery Foundation, two nonprofit organizations founded to support Duchenne muscular dystrophy, or DMD, research. Under the agreement we will seek to identify novel disease-modifying multi-targeted treatments for DMD, the most common childhood form of muscular dystrophy. Under the terms of the agreement, we are eligible to receive up to $3.45 million in research funding and reimbursement of additional expenses during the term of the DMD research and development project. We retain worldwide commercialization rights for any product candidates discovered or developed under the agreement, and we will own all new intellectual property and data generated by the research and development project. FederalU.S. Army Medical Research Institute for Infectious DiseasesReceived a $1.3 million research grant from the U.S. Army Medical Research Institute for Infectious Diseases (USAMRIID) for the research and discovery of potential treatments for viral hemorrhagic fevers (VHFs). VHFs are caused by several distinct families of viruses that affect multiple organ systems in the body, and are often accompanied by hemorrhage (bleeding). Many of these viruses cause severe, life-threatening disease. National Institute of Allergy and Infectious Diseases (NIAID)In April 2005, CombinatoRx was awarded a $4.4 million research grant from the National Institute of Allergy and Infectious Diseases (NIAID) (Full News Release). This cooperative research grant with the National Institute of Health (NIH) will apply the CombinatoRx cHTS™ technology to identify potential anti-toxin therapeutics that could be used to alleviate the life-threatening symptoms associated with anthrax exposure.
If you have business development inquiries, please contact bizdev@combinatorx.com. |
|
|
 |
